Moderna Inc. MRNA shares ticked higher in the extended session Wednesday after the biotech company said the first batch of data from its late-stage test of an experimental COVID-19 vaccine was ready for analysis. Moderna shares rose 1% after hours, following an 8.4% rise to close the regular session at $82.44. The company said the first batch of data, which is being sent to a data-safety monitoring board, is on 53 patients, some of whom were given the vaccine, the others a placebo. In late October, Moderna completed enrollment of 30,000 participants in the study, and said it was “actively preparing” for a launch of the vaccine. Moderna shares are up 324% for the year, compared with a 10.6% rise by the S&P 500 index SPX.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.